Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$85.16

-0.3 (-0.35%)

, ABBV

AbbVie

$72.02

0.55 (0.77%)

04:55
08/10/17
08/10
04:55
08/10/17
04:55

Leerink to hold a bus tour

West Coast Biotech Bus Tour, begins in San Francisco traveling throughout the city visiting with various biotech companies on August 8 & 9, and on the third day, August 10, travels to Los Angeles to visit with biotech companies located in that city.

BMRN

BioMarin

$85.16

-0.3 (-0.35%)

ABBV

AbbVie

$72.02

0.55 (0.77%)

AKAO

Achaogen

$18.15

-0.58 (-3.10%)

ARNA

Arena Pharmaceuticals

$20.73

-0.52 (-2.45%)

IMDZ

Immune Design

$9.05

-0.95 (-9.50%)

FPRX

Five Prime

$28.51

-0.69 (-2.36%)

TBPH

Theravance Biopharma

$23.88

-5.91 (-19.84%)

GILD

Gilead

$73.90

0.63 (0.86%)

CALA

Calithera Biosciences

$12.83

-1.775 (-12.16%)

NBIX

Neurocrine

$54.78

1.13 (2.11%)

SGEN

Seattle Genetics

$48.72

-0.34 (-0.69%)

IONS

Ionis Pharmaceuticals

$48.06

-0.25 (-0.52%)

XNCR

Xencor

$22.40

-0.89 (-3.82%)

AMGN

Amgen

$173.55

-0.14 (-0.08%)

PBYI

Puma Biotechnology

$79.50

-1.95 (-2.39%)

  • 10

    Aug

  • 14

    Aug

  • 15

    Aug

  • 28

    Aug

  • 08

    Sep

  • 11

    Sep

  • 14

    Sep

  • 18

    Oct

  • 02

    Dec

  • 03

    Feb

  • 17

    May

BMRN BioMarin
$85.16

-0.3 (-0.35%)

07/27/17
BERN
07/27/17
INITIATION
BERN
Market Perform
BioMarin initiated with a Market Perform at Bernstein
Bernstein analyst Vincent Chen started coverage of BioMarin with a Market Perform rating and an $89 price target. He says that its valuation is "full."
07/27/17
07/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kinder Morgan (KMI) initiated with a Neutral at Mizuho. 2. Alpine Immune Sciences (ALPN) initiated with a Buy at Ladenburg. 3. Synaptics (SYNA) resumed with an Outperform at Cowen. 4. BioMarin (BMRN) and Ultragenyx (RARE) were initiated with a Market Perform at Bernstein. 5. Keane Group (FRAC) and ProPetro Holding (PUMP) were initiated with an Overweight at Capital One. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/20/17
RHCO
07/20/17
NO CHANGE
RHCO
Sarepta price target raised to $56 from $45 at SunTrust
SunTrust analyst Edward Nash raised his price target on Sarepta (SRPT) after Sarepta and BioMarin (BMRN) executed a license agreement that provides Sarepta Therapeutics with global exclusive rights to BioMarin's DMD patent estate for EXONDYS 51 and all future exon-skipping products. The analyst says that EXONDYS 51 "continued to demonstrate strong momentum" in Q2, and he keeps a Buy rating on Sarepta.
07/19/17
RHCO
07/19/17
NO CHANGE
RHCO
Sarepta deal 'highly positive,' says SunTrust
After Sarepta (SRPT) and BioMarin (BMRN) announced a license agreement, SunTrust analyst Edward Nash says the deal resolves a patent dispute between the companies and terminates Sarepta's IP overhang. The analyst says that the deal "effectively provided Sarepta with exclusive rights to BioMarin's DMD patent estate," while the single digit royalty payments to BioMarin are also favorable for Sarepta. He calls the deal "highly positive" for Sarepta and keeps a Buy rating on the stock. .
ABBV AbbVie
$72.02

0.55 (0.77%)

06/22/17
SOCG
06/22/17
UPGRADE
SOCG
Buy
AbbVie upgraded to Buy from Hold at Societe Generale
07/20/17
FBCO
07/20/17
NO CHANGE
Target $74
FBCO
Neutral
AbbVie price target raised to $74 from $65 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for AbbVie to $74 from $65 ahead of Q2 results. The analyst reiterates a Neutral rating on the shares as he believes the company's strong near-term growth profile is offset by questions over Humira's longevity and sees the risk/reward around other pipeline assets as being balanced.
07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.
08/02/17
PIPR
08/02/17
NO CHANGE
Target $7
PIPR
Overweight
Imbruvica approval in graft versus host positive for Kadmon, says Piper Jaffray
After the FDA expanded the approval of AbbVie (ABBV) and Johnson & Johnson's (JNJ) Imbruvica for the treatment of adults with chronic graft versus host disease, or cGVHD, Piper Jaffray analyst Edward Tenthoff said he views the news as positive for Kadmon's KD025. Imbruvica is tough for patients to tolerate, said Tenthoff, who sees an opportunity for KD025 to more safely treat cGVHD patients. He keeps an Overweight rating and $7 price target on Kadmon shares.
AKAO Achaogen
$18.15

-0.58 (-3.10%)

03/17/17
RHCO
03/17/17
NO CHANGE
Target $31
RHCO
Buy
Achaogen short report 'fundamentally flawed,' says SunTrust
SunTrust analyst Edward Nash says a short report posted earlier this week on website Seeking Alpha is "short on facts and fundamentally flawed." The report's conclusion on the EPIC and CARE studies is incorrect, at best, Nash tells investors in a research note. Further, the report made inaccurate claims about the FDA's requirements for plazomicin's new drug application submission, the analyst adds. He reiterates a Buy rating on Achaogen with a $31 price target.
06/15/17
HCWC
06/15/17
INITIATION
Target $29
HCWC
Buy
Achaogen initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce started Achaogen with a Buy rating and $29 price target. The company has an "impressive pipeline of novel antibiotics for serious, hard-to-treat, multi-drug resistant Gram-negative infections," the analyst contends.
03/16/17
RHCO
03/16/17
NO CHANGE
RHCO
Achaogen warning letter should not be major issue, says SunTrust
SunTrust analyst Edward Nash says that a warning letter issued by the FDA to Achaogen's manufacturing partner should be resolved relatively quickly and therefore "should not have significant impact on" the approval of the company's plazomicin drug. The firm reiterates its $31 price target and Buy rating on Achaogen.
03/30/17
AGIS
03/30/17
DOWNGRADE
Target $29
AGIS
Hold
Achaogen downgraded to Hold from Buy at Aegis
Aegis downgraded Achaogen to Hold saying plazomicin is almost fully priced into shares and maintained his $29 price target.
ARNA Arena Pharmaceuticals
$20.73

-0.52 (-2.45%)

06/27/17
06/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Alex Yao resumed coverage of Alibaba (BABA) Group with an Overweight rating and $190 price target following a period of restriction. The rating is unchanged and the price target is raised from $140. 2. SunTrust analyst Terry Tillman initiated Salesforce (CRM) with a Buy and a $110 price target and views its as a core holding for large-cap investors. 3. Citi analyst Joel Beatty started Arena Pharmaceuticals (ARNA) with a Buy rating and $23 price target. 4. Deutsche Bank analyst Bryan Kraft started Lionsgate Class A (LGF.A) shares with a Hold rating and $29 price target. 5. Cantor Fitzgerald analyst Louise Chen assumed coverage of Amarin (AMRN) with an Overweight rating and $10 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/17
LEER
07/11/17
NO CHANGE
Target $53
LEER
Outperform
Arena Pharmaceuticals price target raised to $53 from $47 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Arena Pharmaceuticals to $53 from $47 after the company reported "promising" topline results from its Phase 2 ralinepag study in pulmonary arterial hypertension that surpassed the benchmark established by its competitor selexipag. On the heels of ralinepag data, the analyst believes investors will begin to assign greater value to the company's proprietary pipeline that could present further upside in not only mass-market indications like ulcerative colitis and pain, but also in the rare manifestations including pyoderma gangrenosum and extraintestinal manifestations. Schwartz reiterates an Outperform rating on the shares.
07/11/17
SBSH
07/11/17
NO CHANGE
Target $37
SBSH
Buy
Arena Pharmaceuticals price target raised to $37 from $23 at Citi
07/11/17
JMPS
07/11/17
NO CHANGE
JMPS
Arena Pharmaceuticals price target raised to $36 from $27 at JMP Securities
JMP Securities analyst Jason Butler says that the Phase 2 results of Arena's Ralinepag in PAH indicates that it has "a compelling clinical profile" that supports "a blockbuster commercial opportunity." The analyst adds that the drug can become "the best-in-class oral prostacyclin receptor agonist." He raised his price target on the shares to $36 from $27 and keeps an Outperform rating on the stock.
IMDZ Immune Design
$9.05

-0.95 (-9.50%)

FPRX Five Prime
$28.51

-0.69 (-2.36%)

10/25/16
SBSH
10/25/16
INITIATION
Target $65
SBSH
Buy
Five Prime initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Five Prime Therapeutics with a Buy rating and $65 price target. The company has "multiple shots" on goal in various cancers, Karnauskas tells investors in a research note. She believes investors will assign higher value to the Cabiralizumab program once combo data with Opdivo is seen in 2017. The analyst sees fair value for Five Prime shares in the $65-$80 range.
03/24/17
COWN
03/24/17
INITIATION
COWN
Outperform
Five Prime initiated with an Outperform at Cowen
Cowen analyst Chris Shibutani initiated Five Prime (FPRX) with an Outperform saying its proprietary IO platform is underappreciated by investors and has multiple clinical readouts in 2017 provide catalysts to drive value generation. The analyst said Five Prime's $1.8B out-licensing partnership deal with Bristol Myers (BMY) for Cabiralizumab in 2015 provides validation in supporting its platform.
03/01/17
NOMU
03/01/17
INITIATION
Target $94
NOMU
Buy
Five Prime initiated with a Buy at Nomura
Nomura initiated Five Prime with a Buy and a $94 price target.
TBPH Theravance Biopharma
$23.88

-5.91 (-19.84%)

03/22/17
PIPR
03/22/17
NO CHANGE
Target $42
PIPR
Overweight
Theravance one program away from joining Incyte, says Piper Jaffray
After hosting meetings with management, Piper Jaffray analyst Joshua Schimmer reiterates Theravance Biopharma (TBPH) as a top mid-cap pick. The analyst has an Overweight rating on the shares with a $42 price target. Schimmer increasingly sees Theravance as one of the most likely mid-caps to make the jump to be the next Incyte (INCY). The company is just one major program away from joining the ranks of Incyte and BioMarin (BMRN), he tells investors in a research note.
05/10/17
LEER
05/10/17
NO CHANGE
Target $47
LEER
Outperform
Theravance Biopharma price target raised to $47 from $34 at Leerink
Leerink analyst Geoffrey Porges raised his price target Theravance Biopharma to $47 from $34 after the company reported Q1 financial results and provided an update for investors about its development progress and upcoming milestones. The analyst reiterates an Outperform rating on the shares.
06/16/17
CANT
06/16/17
INITIATION
Target $55
CANT
Overweight
Theravance Biopharma initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Theravance Biopharma with an Overweight rating and $55 price target.
03/29/17
PIPR
03/29/17
NO CHANGE
Target $42
PIPR
Overweight
Mylan news a positive for Theravance, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Mylan's (MYL) complete response letter for its generic version of GlaxoSmithKline's Advair "buys time and will likely preserve some pricing power in the broader respiratory space." This will be important for GSK's commercialization of the closed triple following potential regulatory approval at year end, Schimmer tells investors in a research note. This is also positive for Theravance Biopharma (TBPH), which stands to receive a "meaningful" mid/high single digit royalty on the closed triple, the analyst contends. He reiterates an Overweight rating on Theravance with a $42 price target. The stock is up 49c to $36.47 in afternoon trading.
GILD Gilead
$73.90

0.63 (0.86%)

07/13/17
BARD
07/13/17
NO CHANGE
Target $87
BARD
Outperform
Baird likes Gilead heading into Q2 earnings
Baird analyst Brian Skorney said he likes Gilead heading into Q2 earnings. The analyst said Hep-C sales should beat estimates and predicts its sales decline should be approaching a plateau, which would result in upside to the shares. He said the operating results could provide much needed stability, which should also result in upside. Skorney maintained his Outperform rating and $87 price target on Gilead shares.
07/27/17
COWN
07/27/17
NO CHANGE
Target $90
COWN
Outperform
Gilead results a 'welcome' beat and raise, says Cowen
Cowen analyst Phil Nadeau called the Gilead results a "welcome beat and raise" for what is a very cheap name. The analyst said it may be too early to confidently say the business has stabilized, but his discounted free cash flow analysis suggests the shares remain undervalued. Nadeau reiterated his Outperform rating and $90 price target on Gilead shares.
07/27/17
JPMS
07/27/17
NO CHANGE
Target $85
JPMS
Overweight
Gilead price target raised to $85 from $80 at JPMorgan
JPMorgan analyst Cory Kasimov raised his price target for Gilead Sciences to $85 saying the Q2 beat-and-raise quarter is "encouraging." The HCV franchise is still in decline, but the "resiliency this quarter helps further fuel ample cash generation," Kasimov tells investors in a post-earnings research note. He keeps an Overweight rating on the shares.
07/14/17
LEER
07/14/17
NO CHANGE
LEER
Acquisition of Incyte would make sense for Gilead, says Leerink
Leerink analyst Geoffrey Porges, who noted he has "written extensively about the imperative for Gilead to diversify their portfolio and secure additional pipeline programs," said in a new note to investors that he believes an acquisition of Incyte (INCY) would make sense for Gilead (GILD). At a "reasonable acquisition premium," Gilead could pay $173-$187 per share for Incyte and its earnings would be diluted through 2018, but thereafter would be increased by such a deal, estimated Porges. The analyst, who concluded that Incyte presents a high-risk/high-reward option for Gilead, keeps a Market perform rating on Gilead shares.
CALA Calithera Biosciences
$12.83

-1.775 (-12.16%)

01/24/17
01/24/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tableau (DATA) upgraded to Buy from Neutral at Citi with analyst Walter Pritchard saying consensus estimates for fiscal 2017 look low. Revenue transition impacted numbers more than the Street realized in 2016, Pritchard tells investors in a research note. The analyst raised his price target for the shares to $64 from $50. 2. Agrium (AGU) upgraded to Outperform from Market Perform at Cowen, while CF Industries (CF), Mosaic (MOS), and Potash (POT) were upgraded to Market Perform from Underperform. 3. Calithera Biosciences (CALA) upgraded to Neutral from Sell at Citi with analyst Robyn Karnauskas citing her conversation with management. Management now appears more open to partnering, Karnauskas tells investors in a research note. 4. Home Bancshares (HOMB) upgraded to Buy from Hold at Sandler O'Neill. 5. Amicus (FOLD) upgraded to Outperform from Neutral at Baird with analyst Michael Ulz saying the company removed two overhangs by providing regulatory clarity for Galafold in the U.S. as well as a strengthening its balance sheet. Ulz raised his price target to $10 from $7 on Amicus shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/03/17
LEER
04/03/17
INITIATION
Target $16
LEER
Outperform
Calithera Biosciences reinstated with an Outperform at Leerink
Leerink analyst Jonathan Chang resumed coverage of Calithera Biosciences with an Outperform rating and a $16 price target saying it is well positioned to execute with multiple sources of upside.
01/31/17
RHCO
01/31/17
NO CHANGE
RHCO
Incyte price target raised to $140 from $115 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Incyte (INCY), citing "increased pipeline & technology value" as data releases and PDUFA dates approach. Additionally, the analyst is upbeat on the company's global collaboration deal with Calithera (CALA), saying that the deal expands Incyte's "reach into the (immuno-oncology) space." The analyst reiterates a Buy rating on Incyte.
06/12/17
HCWC
06/12/17
NO CHANGE
Target $19
HCWC
Buy
Calithera Biosciences price target raised to $19 from $14 at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak raised his price target for Calithera Biosciences to $19 saying data suggest CB-1158 "demonstrates promising arginase inhibition." The analyst believes that twice-daily CB-1158 can effectively reduce arginase activity, resulting in "meaningful increases in plasma arginine activity and preliminary evidence of immune modulation." He keeps a Buy rating on Calithera.
NBIX Neurocrine
$54.78

1.13 (2.11%)

07/05/17
OPCO
07/05/17
NO CHANGE
Target $70
OPCO
Outperform
Neurocrine Ingrezza 'holds steady' after competitor data, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Teva's (TEVA) Austedo could become a competitor to Neurocrine's (NBIX) Ingrezza with a PDUFA date for the tardive dyskinesia indication on August 30, 2017. However, the analyst sees Ingrezza as well positioned and reiterates an Outperform rating and $70 price target on Neurocrine's shares. A key factor to follow beyond the short trials will be real-life performance considering the number needed to treat to observe a 50% AIMS improvement was 5 for Austedo and 4 for Ingrezza, he contends.
05/24/17
LEER
05/24/17
NO CHANGE
Target $66
LEER
Outperform
Neurocrine's pediatric Tourette program 'is not dead,' says Leerink
Leerink analyst Paul Matteis says that despite last night's Phase 2 failure, Neurocrine Biosciences' Ingrezza in pediatric Tourette syndrome program "is not dead." The mechanistic rationale for valbenazine in Tourette's is still strong, Matteis tells investors in a research note. He thinks there was about $3-$4 for pediatrics priced into the stock. The analyst maintains 30% odds of success for valbenazine in Tourette's, but pushed sales out two years to 2022. He lowered his price target for Neurocrine shares to $66 from $68 and reiterates an Outperform rating on the name.
05/24/17
BMOC
05/24/17
NO CHANGE
BMOC
Neurocrine should be bought on weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya recommends buying Neurocrine on weakness after mixed data for the company's Ingrezza in pediatric Tourette's was reported. The analyst says that the data was sufficient to justify the launch of Phase 2b trials, and he believes that the company could obtain a licensing deal in Europe for the drug. He keeps a $75 price target and an Outperform rating on the stock.
05/30/17
05/30/17
NO CHANGE
Target $66

Buy
Jefferies survey shows restrictions for Neurocrine's Ingrezza
Jefferies analyst Biren Amin said his firm's survey of 25 payors found that the majority of payors plan to restrict Neurocrine's Ingrezza to moderate-severe tardive dyskinesia patients. Despite this feedback, consensus estimates for 2017 and 2018 appear achievable, Amin tells investors in a research note. He keeps a Buy rating on Neurocrine with a $66 price target.
SGEN Seattle Genetics
$48.72

-0.34 (-0.69%)

06/19/17
PIPR
06/19/17
NO CHANGE
Target $48
PIPR
Neutral
Seattle Genetics price target lowered to $48 from $57 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Seattle Genetics to $48 after the company announced the discontinuation of the Phase III Cascade trial in acute myeloid leukemia. The analyst views the news as a negative surprise and removed SGN-CD33A from his model. He keeps a Neutral rating on Seattle Genetics. The stock in early trading is down 9%, or $5.62, to $58.90.
06/20/17
LEER
06/20/17
NO CHANGE
Target $66
LEER
Outperform
Seattle Genetics price target lowered to $66 from $74 at Leerink
Leerink analyst Michael Schmidt lowered his price target for Seattle Genetics to $66 after the company discontinued SGN-CD33A in front-line, elderly acute myeloid leukemia patients. The news increases the importance of positive Adcetris ECHELON-1 trial in front-line Hodgkin lymphoma later this year, which will be critical for the company to accelerate top-line growth, Schmidt tells investors in a research note. He keeps an Outperform rating on Seattle Genetics.
06/26/17
JPMS
06/26/17
NO CHANGE
JPMS
Neutral
Seattle Genetics data lack 'wow factor,' says JPMorgan
JPMorgan analyst Cory Kasimov says that while this morning's Phase 3 ECHELON-1 study in frontline Hodgkin's Lymphoma from Seattle Genetics don't necessarily have the "wow factor," recent conversations with key opinion leaders indicate the data will be enough to drive significant uptake in the setting. The analyst keeps a Neutral rating on shares of Seattle Genetics.
06/26/17
PIPR
06/26/17
NO CHANGE
Target $48
PIPR
Neutral
Piper says Seattle Genetics data good enough to warrant ADCETRIS approval
Piper Jaffray analyst Edward Tenthoff noted that Seattle Genetics' Phase 3 ECHELON-1 data showed only a "modest" benefit but he still thinks the data is "good enough" to warrant approval for ADCETRIS in a frontline indication, likely next year. Tenthoff, who forecasts ADCETRIS sales of about $295M this year and $375M in 2018, keeps a Neutral rating and $48 price target on Seattle Genetics shares.
IONS Ionis Pharmaceuticals
$48.06

-0.25 (-0.52%)

07/27/17
BERN
07/27/17
INITIATION
BERN
Market Perform
Ionis Pharmaceuticals initiated with a Market Perform at Bernstein
Bernstein analyst Vincent Chen started coverage of Ionis with a $57 price target and a Market Perform rating.
07/25/17
NEED
07/25/17
NO CHANGE
NEED
Ionis selloff a buying opportunity, says Needham
Needham analyst Chad Messer recommends using today's selloff in shares of Ionis Pharmaceuticals (IONS) as a buying opportunity. He believes concerns over the sustainability of Biogen's (BIIB) Spinraza launch overlook the longer term opportunity. The analyst has Buy rating on Ionis shares, which are down 11% in midday trading to $53.16.
07/26/17
BMOC
07/26/17
NO CHANGE
BMOC
Ionis Pharmaceuticals should be bought on weakness, says BMO Capital
BMO Capital analyst Do Kim recommends buying Ionis on weakness following Biogen's comments on Spinraza. The analyst thinks that Spinraza can grow in Type and Type 3. Kim keeps an Outperform rating on Ionis.
07/25/17
WELS
07/25/17
NO CHANGE
Target $75
WELS
Outperform
Ionis challenges to Spinraza dosing addressable, says Wells Fargo
Wells Fargo analyst Jim Birchenough noted that Ionis (IONS) partner Biogen (BIIB) made comments that suggested slowing growth for Spinraza in the future due to technical challenges to dosing in patients with spinal surgeries. However, he understands that Ionis has seen initial success in dosing patients with type 2 SMA and spinal surgery and believes these patients will be viable candidates for Spinraza even though the process is more involved. Birchenough, who thinks the drug's impressive growth and broadening use and reimbursement more than offsets a hurdle dosing certain patients, raised his price target on Ionis shares to $75 and keeps an Outperform rating on the stock.
XNCR Xencor
$22.40

-0.89 (-3.82%)

10/04/16
PIPR
10/04/16
INITIATION
Target $35
PIPR
Overweight
Xencor initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff started Xencor with an Overweight rating and $35 price target. The analyst views the company's next-gen and bispecific antibodies as "exciting."
11/28/16
ADAM
11/28/16
NO CHANGE
Target $32
ADAM
Buy
Xencor price target raised to $32 from $27 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Xencor to $32 from $27 citing its XmAb pipeline and attractive bispecifics capabilities and the company's mechanistic rationale for treating IgG4-RD with XmAb5871. Lee reiterated her Buy rating on Xencor shares.
12/08/16
LEER
12/08/16
NO CHANGE
Target $35
LEER
Outperform
Xencor price target raised to $35 from $30 at Leerink
Leerink analyst Michael Schmidt raised his price target for Xencor to $35 from $30 following its recent $127M equity financing, which should enable the company to accelerate and broaden development of its bispecific antibody pipeline as well as support potential pivotal trials of lead product XmAb5871 in IgG4-related disease. The analyst remains positive on Xencor's outlook as he believes the company's differentiated antibody engineering platform will continue to garner strategic interest while existing partnered and proprietary pipeline programs mature, providing upside to the current valuation. He reiterates an Outperform rating on the shares.
03/01/17
NOMU
03/01/17
INITIATION
Target $21
NOMU
Neutral
Xencor initiated with a Neutral at Nomura
Nomura initiated Xencor with a Neutral and a $21 price target.
AMGN Amgen
$173.55

-0.14 (-0.08%)

07/26/17
BMOC
07/26/17
DOWNGRADE
BMOC
Market Perform
Amgen downgraded to Market Perform from Outperform at BMO Capital
07/26/17
BMOC
07/26/17
DOWNGRADE
BMOC
Market Perform
Amgen downgraded on valuation lack of near-term catalysts at BMO Capital
As noted earlier, BMO Capital downgraded Amgen to Market Perform from Outperform. Analyst M. Ian Somaiya downgraded the stock based on valuation and his belief that American College of Cardiology guidelines probably won't be updated until late 2018, likely preventing a positive turning point in Repatha sales until 2019. Target $199.
07/26/17
OPCO
07/26/17
NO CHANGE
Target $203
OPCO
Outperform
Amgen price target raised to $203 from $189 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Amgen to $203 from $189 after the company reported "strong" Q2 results. The analyst reiterates an Outperform rating on the shares.
07/18/17
PIPR
07/18/17
NO CHANGE
Target $14
PIPR
Overweight
Piper says Array deal with Amgen 'another example' of successful partnering
Commenting on Array Biopharma's (ARRY) announcement of a preclinical autoimmune partnership deal with Amgen (AMGN), Piper Jaffray analyst Edward Tenthoff called the agreement "yet another example of Array successfully partnering its discoveries" and raising non-dilutive capital. Tenthoff keeps an Overweight rating and $14 price target on Array Biopharma shares.
PBYI Puma Biotechnology
$79.50

-1.95 (-2.39%)

07/19/17
LEER
07/19/17
NO CHANGE
Target $125
LEER
Outperform
Puma Biotechnology price target raised to $125 from $115 at Leerink
Post-FDA approval of Nerlynx, Leerink analyst Michael Schmidt raised his price target for Puma Biotechnology to $125 from $115 driven by a higher Nerlynx forecast now of $1.6B U.S. peak sales. The analyst reiterates an Outperform rating on the shares.
08/01/17
LEER
08/01/17
NO CHANGE
LEER
Outperform
Puma selloff today brings buying opportunity, says Leerink
Puma Biotechnology shares are down 11% after the company announced last night that its lead product Nerlyx is commercially available by prescription in the United States. Puma has frequently been discussed as a potential takeover target, and some investors associate the availability of Nerylyx negatively with respect to the sales prospects of the company, Leerink analyst Michael Schmidt tells investors in an intraday research note. He says that while a potential buyout could yield near-term upside of 50%-75%, the timing of acquisitions are always difficult to predict accurately. Schmidt's thesis on the shares is based on underlying fundamentals, which he views as "compelling." The analyst reiterates an Outperform rating on Puma and recommends buying the stock on today's selloff. The shares in midday trading are down 11%, or $10.22, to $84.83.
08/01/17
LEER
08/01/17
NO CHANGE
LEER
Outperform
Puma Biotechnology selloff today a buying opportunity, says Leerink
08/01/17
JPMS
08/01/17
NO CHANGE
JPMS
Overweight
Puma 'soft launch' of Nerlynx underway, says JPMorgan
JPMorgan analyst Cory Kasimov says Puma Biotechnology management clarified to him that Nerlynx is now available via a "soft launch" with the full promotional launch still expected in September. Last night's announcement was triggered by "post approval inbound interest to multiple people within the company for access to the product," Kasimov tells investors in a research note. He reiterates an Overweight rating on shares of Puma.

TODAY'S FREE FLY STORIES

KO

Coca-Cola

$45.71

-0.84 (-1.80%)

08:46
11/20/17
11/20
08:46
11/20/17
08:46
Recommendations
Coca-Cola analyst commentary  »

Coca-Cola investor day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$40.82

8.97 (28.16%)

08:45
11/20/17
11/20
08:45
11/20/17
08:45
Recommendations
Foot Locker analyst commentary  »

Foot Locker price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:45
11/20/17
11/20
08:45
11/20/17
08:45
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

JNJ

Johnson & Johnson

$138.00

-0.87 (-0.63%)

08:43
11/20/17
11/20
08:43
11/20/17
08:43
Hot Stocks
EU extends license for Janssen's Zytiga plus prednisone »

Janssen-Cilag…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

LIVN

LivaNova

$84.32

0.04 (0.05%)

08:42
11/20/17
11/20
08:42
11/20/17
08:42
Recommendations
LivaNova analyst commentary  »

LivaNova received fair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 01

    Dec

MNST

Monster Beverage

$62.17

0.17 (0.27%)

, KO

Coca-Cola

$45.71

-0.84 (-1.80%)

08:40
11/20/17
11/20
08:40
11/20/17
08:40
Downgrade
Monster Beverage, Coca-Cola rating change  »

Monster Beverage…

MNST

Monster Beverage

$62.17

0.17 (0.27%)

KO

Coca-Cola

$45.71

-0.84 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NQ

NQ Mobile

$4.05

-0.05 (-1.22%)

08:40
11/20/17
11/20
08:40
11/20/17
08:40
Hot Stocks
NQ Mobile provides update on FL Mobile Divestment »

NQ Mobile provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENSG

Ensign Group

$23.77

0.22 (0.93%)

08:38
11/20/17
11/20
08:38
11/20/17
08:38
Recommendations
Ensign Group analyst commentary  »

Ensign Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

$20.29

0.03 (0.15%)

, CAVM

Cavium

$75.83

-0.47 (-0.62%)

08:37
11/20/17
11/20
08:37
11/20/17
08:37
Hot Stocks
Marvell: Cavium deal doesn't include divestitures, changes to Cavium's portfolio »

On the conference call…

MRVL

Marvell

$20.29

0.03 (0.15%)

CAVM

Cavium

$75.83

-0.47 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

BKS

Barnes & Noble

$7.45

0.35 (4.93%)

08:35
11/20/17
11/20
08:35
11/20/17
08:35
Hot Stocks
Barnes & Noble announces Black Friday weekend deals »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

ARAY

Accuray

$4.80

-0.1 (-2.04%)

08:35
11/20/17
11/20
08:35
11/20/17
08:35
Technical Analysis
Technical View: Accuray rallies in pre-market »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$2.88

0.02 (0.70%)

08:34
11/20/17
11/20
08:34
11/20/17
08:34
Hot Stocks
Genius Brands signs multiple content sales deals for children's programming »

Genius Brands expands the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$34.95

-0.33 (-0.94%)

08:34
11/20/17
11/20
08:34
11/20/17
08:34
Initiation
Aimmune initiated  »

Aimmune initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

WOR

Worthington

$40.24

0.03 (0.07%)

08:33
11/20/17
11/20
08:33
11/20/17
08:33
Hot Stocks
WAVE to sell EMEA, Pacific Rim units »

Worthington (WOR)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIV

On Track Innovations

$1.13

-0.01 (-0.88%)

08:32
11/20/17
11/20
08:32
11/20/17
08:32
Hot Stocks
On Track Innovations: UNO 6 selected by CityEV as cashless payment solution »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MDSO

Medidata

$68.64

-0.85 (-1.22%)

08:32
11/20/17
11/20
08:32
11/20/17
08:32
Hot Stocks
Medidata, MEL MEDICAL announce multi-year Medidata eTMF agreement »

Medidata announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

PNTR

Pointer Telocation

$17.55

-0.2 (-1.13%)

08:30
11/20/17
11/20
08:30
11/20/17
08:30
Downgrade
Pointer Telocation rating change  »

Pointer Telocation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZH

Beazer Homes

$20.50

0.04 (0.20%)

08:29
11/20/17
11/20
08:29
11/20/17
08:29
Recommendations
Beazer Homes analyst commentary  »

Beazer Homes price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:28
11/20/17
11/20
08:28
11/20/17
08:28
Conference/Events
The Board of Governors of the Federal Reserve System holds a closed meeting »

The Board of Governors of…

DG

Dollar General

$85.50

0.59 (0.69%)

, DLTR

Dollar Tree

$94.61

-0.02 (-0.02%)

08:28
11/20/17
11/20
08:28
11/20/17
08:28
Recommendations
Dollar General, Dollar Tree analyst commentary  »

Dollar General price…

DG

Dollar General

$85.50

0.59 (0.69%)

DLTR

Dollar Tree

$94.61

-0.02 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 07

    Dec

OMI

Owens & Minor

$19.14

0.23 (1.22%)

08:27
11/20/17
11/20
08:27
11/20/17
08:27
Recommendations
Owens & Minor analyst commentary  »

Owens & Minor price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIZZ

National Beverage

$102.23

0.32 (0.31%)

08:26
11/20/17
11/20
08:26
11/20/17
08:26
Upgrade
National Beverage rating change  »

National Beverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$93.61

-0.86 (-0.91%)

08:25
11/20/17
11/20
08:25
11/20/17
08:25
Recommendations
AbbVie analyst commentary  »

AbbVie estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$19.13

0.09 (0.47%)

08:25
11/20/17
11/20
08:25
11/20/17
08:25
Downgrade
Deutsche Bank rating change  »

Deutsche Bank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AMZN

Amazon.com

$1,129.88

-7.41 (-0.65%)

, CVS

CVS Health

$70.68

0.42 (0.60%)

08:25
11/20/17
11/20
08:25
11/20/17
08:25
Recommendations
Amazon.com, CVS Health, Walgreens Boots Alliance, Cardinal Health, McKesson, AmerisourceBergen, Thermo Fisher, Henry Schein, Patterson Companies analyst commentary  »

Amazon disruption of…

AMZN

Amazon.com

$1,129.88

-7.41 (-0.65%)

CVS

CVS Health

$70.68

0.42 (0.60%)

WBA

Walgreens Boots Alliance

$71.25

-0.05 (-0.07%)

CAH

Cardinal Health

$57.51

0.09 (0.16%)

MCK

McKesson

$142.13

-0.57 (-0.40%)

ABC

AmerisourceBergen

$78.84

-1.09 (-1.36%)

TMO

Thermo Fisher

$190.17

-0.44 (-0.23%)

HSIC

Henry Schein

$69.12

-0.39 (-0.56%)

PDCO

Patterson Companies

$36.04

-0.03 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

  • 12

    Dec

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.